Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aprea Therapeutics, Inc.APRE · Entity 7948 | SVP, Chief Commercial Officer | February 25, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aprea Therapeutics, Inc.
Report date February 25, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,000 |
Reported balance
After 2021-02-25 transaction · row 1
1 source rowRow 1 · 2021-02-25 · Grant · Acquired 16,000 · Balance 16,000 F1: These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 5,333 shares on February 25, 2022, (ii) 5,333 shares on February 25, 2023 and 5,334 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2031-02-25 | Direct | 66,000 |
Reported balance
After 2021-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-25 · Grant · Acquired 66,000 · Balance 66,000 F2: Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 5,333 shares on February 25, 2022, (ii) 5,333 shares on February 25, 2023 and 5,334 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2: Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2021 Filed Mar 2, 2021 00:10 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 66,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006735 · form4.xml · derivative · entry 2 Wessels Gregory S. · CIK 0001824615 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires 2031-02-25 F2 · derivative.exercise_date: Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:10 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006735 · form4.xml · nonDerivative · entry 1 Wessels Gregory S. · CIK 0001824615 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · shares: These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 5,333 shares on February 25, 2022, (ii) 5,333 shares on February 25, 2023 and 5,334 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:05 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 14,700 | $0.00 Strike: $28.75 | $0.00 |
DisclosureSEC source: 0000905148-20-001030 · form4.xml · derivative · entry 1 Wessels Gregory S. · CIK 0001824615 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,700 Underlying: Common Stock · 14,700 shares Expires 2030-09-16 F1 · derivative.exercise_date: Twenty-five percent of these options vest on September 16, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.